Volume : 10, Issue : 10, October – 2023
Title:
IRRADIATED BLOOD PRODUCTS, INDICATIONS AND COMPLICATIONS – REVIEW
Authors :
Majed Fisal Doobi , Waheed Ayidh Mohammed AlQurashi, Majed Abdullah Saeed Alghamdi, Abdullah Siddiq Saeed Mahdi, Saad Fawaz Bin Khatim Alghufayri, Abdulhaleem Abdulrazaq Shahbahai, Maher Mohammed Rashed Alsubhi, Ahmad abdulghaffar abdulghafour, Abdullah Ali Saad AlQarni, Fuad Abdulhamed Abdulsabor Bokhary
Abstract :
Red blood cell transfusions are administered as a therapeutic intervention for the management of hemorrhage and to enhance the delivery of oxygen to bodily tissues. The administration of red blood cell transfusions should be determined by the patient’s clinical status. Narrative review conducted throughout the databases such as PubMed, for all relevant studies that were published up to the end of 2022.
Transfusions of blood products ought to be administered in accordance with established protocols and clinical evaluation, while endeavors should be made to prevent the unnecessary administration of transfusions. Over the past few decades, the safety of transfusions has significantly improved due to advancements in component preparation methods. One notable example is the application of leukoreduction to red blood cells (RBC) or platelets, which has been found to considerably decrease the incidence of febrile non-hemolytic transfusion reactions (FNHTR) and human leukocyte antigen (HLA) alloimmunization-related problems. The implementation of these product adjustments is primarily observed in affluent nations, although remains universally absent in the poor world. Specific modifications that should be implemented for patients with particular blood product requirements include irradiation, washing of red blood cells and platelets, and depletion of platelets from plasma.
Cite This Article:
Please cite this article in Majed Fisal Doobi et al . Irradiated Blood Products, Indications And Complications – Review, Indo Am. J. P. Sci, 2023; 10 (10).
Number of Downloads : 10
References:
1. Hardwick J. Blood processing: Introduction to blood transfusion technology. ISBT Sci Ser. 2008;3:148–76.
2. New Delhi: National Aids Control Organization, Ministry of Health and Family welfare Government of India; 2007. Standards for Blood Banks and Blood Transfusion Services; pp. 47–50.
3. Moog R. A new technology in blood collection: Multicomponent apheresis. In: Peterson BR, editor. New Developments in Blood Transfusion Research. New York: Nova Science Publishers, Inc; 2006. pp. 141–6.
4. Lotens A, Najdovski T, Cellier N, Ernotte B, Lambermont M, Rapaille A. New approach to ‘top-and-bottom’ whole blood separation using the multiunit TACSI WB system: Quality of blood components. Vox Sang. 2014;107:261–8.
5. Agbaht K, Altintas ND, Topeli A, Gokoz O, Ozcebe O. Transfusion-associated graft-versus-host disease in immunocompetent patients: case series and review of the literature. Transfusion. 2007; 47: 1405–11.
6. Aoun E, Shamseddine A, Chehal A, Obei M, Taher A. Transfusion-associated GVHD: 10 years’ experience at the American University of Beirut-Medical Center. Transfusion. 2003; 43: 1672–6.
7. Maitta RW, Vasovic LV, Mohandas K, Music-Aplenc L, Bonzon-Adelson A, Uehlinger J. A safe therapeutic apheresis protocol in paediatric patients weighing 11 to 25 kg. Vox Sang. 2014
8. Matthes G, Ingilizov M, Dobao ML, Marques S, Callaert M. Red cell apheresis with automated in-line filtration. Transfus Med Hemother. 2014;41:107–13.
9. Klein HG, Anstee DJ, editors. 11th ed. Massachusetts: Blackwell Publishing Ltd; 2005. Mollison’s Blood Transfusion in Clinical Medicine; p. 27.
10. Kopolovic I, Ostro J, Tsubota H, Lin Y, Cserti-Gazdewich CM, Messner HA, et al. A systematic review of transfusion-associated graft-versus-host disease. Blood. 2015; 126: 406–14.
11. Uchida S, Tadokoro K, Takahashi M, Yahagi H, Satake M, Juji T. Analysis of 66 patients with definitive transfusion-associated graft-versus-host disease and the effect of universal irradiation of blood. Transfus Med. 2013; 23: 416–22.
12. Williamson LM, Stainsby D, Jones H, Love E, Chapman CE, Navarrete C, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion. 2007; 47: 1455–67.
13. Garraud O, Tariket S, Sut C, Haddad A, Aloui C, Chakroun T, Laradi S, Cognasse F. Transfusion as an Inflammation Hit: Knowns and Unknowns. Front Immunol. 2016;7:534.
14. Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion. 2001 Aug;41(8):997-1000.
15. Pineda AA, Taswell HF. Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature. Transfusion. 1975 Jan-Feb;15(1):10-5.
16. Sandler SG, Mallory D, Malamut D, Eckrich R. IgA anaphylactic transfusion reactions. Transfus Med Rev. 1995 Jan;9(1):1-8.
17. Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness LG, Kopko PM, McFarland JG, Nathens AB, Silliman CC, Stroncek D., National Heart, Lung and Blood Institute Working Group on TRALI. Transfusion-related acute lung injury: definition and review. Crit Care Med. 2005 Apr;33(4):721-6.
18. Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA class II antibodies in transfusion-related acute lung injury. Transfusion. 2001 Oct;41(10):1244-8.
19. Zhou L, Giacherio D, Cooling L, Davenport RD. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion. 2005 Jul;45(7):1056-63.
20. Popovsky MA. Transfusion and the lung: circulatory overload and acute lung injury. Vox Sang. 2004 Jul;87 Suppl 2:62-5.
21. Savage SA, Sumislawski JJ, Zarzaur BL, Dutton WP, Croce MA, Fabian TC. The new metric to define large-volume hemorrhage: results of a prospective study of the critical administration threshold. J Trauma Acute Care Surg. 2015 Feb;78(2):224-9; discussion 229-30.
22. Khan AI, Patidar GK, Lakshmy R, Makhija N, Talwar S, Hazarika A. Effect of leukoreduction on transfusion-related immunomodulation in patients undergoing cardiac surgery. Transfus Med. 2020 Dec;30(6):497-504.